You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Patent: 10,633,454

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,633,454

Title:	Expression of modified glycoproteins and glycopeptides
Abstract:	The present invention provides recombinant cells that contain a genetic modification to at least one mannosyl transferase gene. As a result of the modification the cells produce a glycoprotein or glycopeptide that has an N-linked glycan profile that is simplified or more easily humanized. The glycoprotein or glycopeptide can have at least 25% fewer high mannose structures on than the glycoprotein or glycopeptide produced by a reference cell. In some embodiments the modification is a deletion or disruption of a mannosyl transferase gene, which can be in an alg3 gene. Therefore, the proteins produced are more useful for the production of therapeutic glycoproteins than those produced by species having foreign or plant-like patterns of glycosylation. The invention also provides compositions of the glycoproteins or glycopeptides and methods of making them.
Inventor(s):	Caiazza; Nicky C. (Rancho Santa Fe, CA)
Assignee:	Conagen Inc. (Bedford, MA)
Application Number:	15/967,202
Patent Claims:	see list of patent claims

Details for Patent 10,633,454

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2036-11-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003	⤷ Try a Trial	2036-11-01
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018	⤷ Try a Trial	2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2036-11-01
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2036-11-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.